Age significantly influences the sensitivity of SARS-CoV-2 rapid antibody assays

被引:5
|
作者
Irwin, Natalie [1 ,2 ]
Murray, Lyle [1 ,2 ]
Ozynski, Benjamin [2 ,3 ]
Richards, Guy A. [1 ,2 ]
Paget, Graham [1 ,2 ]
Venturas, Jacqueline [1 ,2 ]
Kalla, Ismail [1 ,2 ]
Diana, Nina [1 ,2 ]
Mahomed, Adam [1 ,2 ]
Zamparini, Jarrod [1 ,2 ]
机构
[1] Univ Witwatersrand, Fac Hlth Sci, Dept Internal Med, Johannesburg, South Africa
[2] Charlotte Maxeke Johannesburg Acad Hosp, Dept Med, Johannesburg, South Africa
[3] Wits Hlth Innovat, Johannesburg, South Africa
关键词
COVID-19; antibody; South Africa; diagnostics; age;
D O I
10.1016/j.ijid.2021.07.027
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
BACKGROUND: Point-of-care serological assays are a promising tool in COVID-19 diagnostics but do have limitations. Our study evaluated the sensitivity of five rapid antibody assays and explored factors influencing their sensitivity in detecting SARS-CoV-2-specific IgG and IgM antibodies. METHODS: Finger-prick blood samples from 102 participants, within 2-6 weeks of PCR-confirmed COVID19 diagnosis, were tested for IgG and IgM using five rapid serological assays. The assay sensitivities were compared, and patient factors evaluated in order to investigate potential associations with assay sensitivity. RESULTS: Sensitivity ranged from 36% to 69% for IgG and 13% to 67% for IgM. Age was the only factor significantly influencing the likelihood of a detectable IgG or IgM response. Individuals aged 40 years and older had an increased likelihood of a detectable IgG or IgM antibody response by rapid antibody assay. CONCLUSION: Rapid serological assays demonstrate significant variability when used in a real-world clinical context. There may be limitations in their use for COVID-19 diagnosis among the young. (c) 2021 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ )
引用
收藏
页码:304 / 309
页数:6
相关论文
共 50 条
  • [1] Assessment of commercial SARS-CoV-2 antibody assays, Jamaica
    Butterfield, Tiffany R.
    Bruce-Mowatt, Alrica
    Phillips, Yakima Z. R.
    Brown, Nicole
    Francis, Keisha
    Brown, Jabari
    Walker, Jerome P.
    McKnight, Niel A. L.
    Ehikhametalor, Kelvin
    Taylor, Devon K.
    Bruce, Carl A.
    McGrowder, Donovan
    Wharfe, Gilian
    Sandiford, Simone L.
    Thompson, Tamara K.
    Anzinger, Joshua J.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2021, 105 : 333 - 336
  • [2] Rapid assays of SARS-CoV-2 virus and noble biosensors by nanomaterials
    Liu, Yang
    Li, Yilong
    Hang, Yuteng
    Wang, Lei
    Wang, Jinghan
    Bao, Ning
    Kim, Youngeun
    Jang, Ho Won
    NANO CONVERGENCE, 2024, 11 (01)
  • [3] CRISPR-based assays for rapid detection of SARS-CoV-2
    Javalkote, Vivek S.
    Kancharla, Nagesh
    Bhadra, Bhaskar
    Shukla, Manish
    Soni, Badrish
    Sapre, Ajit
    Goodin, Michael
    Bandyopadhyay, Anindya
    Dasgupta, Santanu
    METHODS, 2022, 203 : 594 - 603
  • [4] Performance Comparison of Five SARS-CoV-2 Antibody Assays for Seroprevalence Studies
    Park, Younhee
    Hong, Ki Ho
    Lee, Su-Kyung
    Hyun, Jungwon
    Oh, Eun-Jee
    Lee, Jaehyeon
    Lee, Hyukmin
    Song, Sang Hoon
    Kee, Seung-Jung
    Kwon, Gye Cheol
    Kim, Su Hwan
    Do, Hyeon-Nam
    Kim, Ah-Ra
    Lee, June-Woo
    Kim, Sung Soon
    Kim, Hyun Soo
    ANNALS OF LABORATORY MEDICINE, 2022, 42 (01) : 71 - +
  • [5] Rapid Antigen Assays for SARS-CoV-2: Promise and Peril
    Truong, Thao T.
    Bard, Jennifer Dien
    Butler-Wu, Susan M.
    CLINICS IN LABORATORY MEDICINE, 2022, 42 (02) : 203 - 222
  • [6] Association of Age With SARS-CoV-2 Antibody Response
    Yang, He S.
    Costa, Victoria
    Racine-Brzostek, Sabrina E.
    Acker, Karen P.
    Yee, Jim
    Chen, Zhengming
    Karbaschi, Mohsen
    Zuk, Robert
    Rand, Sophie
    Sukhu, Ashley
    Klasse, P. J.
    Cushing, Melissa M.
    Chadburn, Amy
    Zhao, Zhen
    JAMA NETWORK OPEN, 2021, 4 (03)
  • [7] Serological Assays for Assessing Postvaccination SARS-CoV-2 Antibody Response
    Mahmoud, Sally A.
    Ganesan, Subhashini
    Naik, Shivaraj
    Bissar, Safaa
    Al Zamel, Isra
    Warren, K. N.
    Zaher, Walid A.
    Khan, Gulfaraz
    MICROBIOLOGY SPECTRUM, 2021, 9 (02):
  • [8] Rapid detection of SARS-CoV-2 using a radiolabeled antibody
    Pirovano, Giacomo
    Ordonez, Alvaro A.
    Jain, Sanjay K.
    Reiner, Thomas
    Carroll, Laurence S.
    Pillarsetty, Naga Vara Kishore
    NUCLEAR MEDICINE AND BIOLOGY, 2021, 98-99 : 69 - 75
  • [9] Rapid Serological Assays and SARS-CoV-2 Real-Time Polymerase Chain Reaction Assays for the Detection of SARS-CoV-2: Comparative Study
    Paradiso, Angelo Virgilio
    De Summa, Simona
    Loconsole, Daniela
    Procacci, Vito
    Sallustio, Anna
    Centrone, Francesca
    Silvestris, Nicola
    Cafagna, Vito
    De Palma, Giuseppe
    Tufaro, Antonio
    Garrisi, Vito Michele
    Chironna, Maria
    JOURNAL OF MEDICAL INTERNET RESEARCH, 2020, 22 (10)
  • [10] Evaluation of serological assays for SARS-CoV-2 antibody testing from dried blood spots collected from cohorts with prior SARS-CoV-2 infection
    Catlett, Beth
    Starr, Mitchell
    Machalek, Dorothy A.
    Danwilai, Thidarat
    Palmer, Michael
    Kelly, Andrew
    Kaldor, John
    Dore, Gregory J.
    Darley, David
    Matthews, Gail
    Cunningham, Philip H.
    JOURNAL OF CLINICAL VIROLOGY PLUS, 2022, 2 (03):